Cambridge Investment Research Advisors’s Pacific Biosciences PACB Stock Holding History

Cambridge Investment Research Advisors’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,854	Closed	-$15K	–	3922
2025 Q3	$15K	Buy	+11,854	New	+$16.1K	﹤0.01%	3698
2024 Q4	–	Sell	-13,130	Closed	-$22K	–	3568
2024 Q3	$22K	Hold	13,130	–	–	﹤0.01%	3362
2024 Q2	$18K	Buy	13,130 +1,196	+10%	+$2.42K	﹤0.01%	3269
2024 Q1	$45K	Sell	11,934 -90,867	-88%	-$532K	﹤0.01%	3218
2023 Q4	$1.01M	Buy	+102,801	New	+$841K	﹤0.01%	1653
2021 Q4	–	Sell	-7,997	Closed	-$204K	–	3248
2021 Q3	$204K	Sell	7,997 -73,668	-90%	-$2.18M	﹤0.01%	2801
2021 Q2	$2.86M	Buy	81,665 +71,526	+705%	+$2.08M	0.01%	926
2021 Q1	$338K	Buy	+10,139	New	+$355K	﹤0.01%	2197
2020 Q4	–	Sell	-17,141	Closed	-$169K	–	2764
2020 Q3	$169K	Buy	+17,141	New	+$98.7K	﹤0.01%	2289

Other funds holding PACB

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cambridge Investment Research Advisors's PACB Position: Q4 2025 in Review

Cambridge Investment Research Advisors sold out of Pacific Biosciences (PACB) in Q4 2025, closing a stake of 11,854 shares — an estimated $15K sold.

Cambridge Investment Research Advisors first reported a position in PACB in Q3 2020 and held it in 9 quarters. The position peaked at $2.86M in Q2 2021. 215 funds tracked by Wall St. Rank hold PACB as of Q4 2025.

Cambridge Investment Research Advisors reported no remaining Pacific Biosciences position as of Q4 2025 after selling out during the quarter.
Cambridge Investment Research Advisors sold 11,854 Pacific Biosciences shares in Q4 2025, an estimated $15K.
Cambridge Investment Research Advisors first reported a position in Pacific Biosciences in Q3 2020 and held it in 9 quarters.
Cambridge Investment Research Advisors's Pacific Biosciences position peaked at $2.86M in Q2 2021.
215 funds tracked by Wall St. Rank held Pacific Biosciences as of Q4 2025.

Based on Cambridge Investment Research Advisors's 13F filing for Q4 2025, filed 5 Feb 2026.